Conatus: Up as FDA approves Histogen application to study hair loss therapy

Histogen

11/05/2020 14:11

** Shares of biotech co  CNAT.O  rise 5.30% to 42 cents
premarket
    ** CNAT's merger partner, Histogen Inc, said U.S. FDA has
approved its Investigational New Drug application for HST 001,
co's lead candidate to treat androgenic alopecia, or male
pattern baldness, that causes early hair loss in men
    ** An IND application is a request to the FDA to allow the
use of an investigational drug on humans 
    ** Application approval keeps co on schedule to begin trials
as planned in June 2020 
    ** Histogen said in January it would merge with CNAT in an
all-stock deal; combined co to be led by Histogen's current
management team and keep the name Histogen Inc

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))